Covid-19 vaccine successful for all age groups – expert

Data from third phase test of coronavirus vaccine developed by Pfizer and BioNTech is showing a 95% protection in all age groups. However, what’s even more important, is that the data is showing 94% protection of adults over 65 years old. An age bracket considered at high risk if transmitted Covid-19 virus. The companies declared in a joint statement.

“Today’s update from Pfizer provides further encouraging news” said Professor Trudie Lang, director of the Global Health Network, Nuffield Department of Medicine, University of Oxford, “The detail on achieving 94% protection in the elderly participants in the trial is particularly excellent news.”

The data continue showing improvement and builds upon the results from last week were preliminary data suggested the vaccine offered 90% protection against Covid-19 and said there were no safety concerns.

Yesterday’s data from Pfizer and BioNTech, suggests the vaccine is 95% effective based on 170 cases of Covid-19 developing in volunteers.

An incredible milestone for science – Prof Lang

Prof Trudie Lang from the University of Oxford describes the situation we are experiencing in science as “a remarkable and very reassuring situation”.

“To go from identifying a new virus to having several vaccines at the point of applying for regulatory approval is an incredible milestone for science,” she said.

Wealthy countries secure first batches

However, concerns are still being raised on poorer countries being left out of the race. The wealthy countries have all but booked the first productions entering into bids with the major research companies.

BBC health correspondent Naomi Grimley, ‘Perhaps one of the biggest problems is that wealthy countries have already swooped in to buy up the first batches that will be ready.’

Hope lays in the UN-backed vaccine research project called COVAX. The aim of the project is to find a vaccine that is accessible to low and middle-income countries. the Oxford-AstraZeneca vaccine, one of the COVAX alliance research teams, is planning to release data from its phase three trial soon. ReplyForward